Sibirioside A exhibits significant neuroprotective properties, making it a compound of interest in the development of treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. It has been shown to reduce oxidative stress in neuronal cells by enhancing antioxidant enzyme activity, thereby helping to prevent neuronal damage. Additionally, Sibirioside A modulates key signaling pathways involved in cell survival and inflammation, suggesting potential use in therapies aimed at mitigating brain injury following stroke or trauma. Its ability to cross the blood-brain barrier further enhances its suitability for central nervous system-targeted applications. Research is ongoing to explore its efficacy in preclinical models of cognitive impairment and neuroinflammation.